Skip to main content
. Author manuscript; available in PMC: 2019 Dec 28.
Published in final edited form as: Cancer Lett. 2018 Sep 19;439:56–65. doi: 10.1016/j.canlet.2018.09.024

Figure 2.

Figure 2.

PI3K inhibition synergizes with Volasertib (BI6727). A, dose-response assays showing increased responses of ATC cell lines to combined PI3K and PLK1 inhibition. B, heat map showing the effect of combining 10nM Volasertib (BI6727) with the corresponding BKM120 dose (from the experiments in A). C, distribution of the Combination Indices at EC75 and EC90 showing synergy in the majority of cell lines analyzed. D, western blot analysis of AKT activation status in the human cell lines utilized.